腾盛博药-B逆市涨逾22% 高盛预计头部企业将不断提高运营效率

新浪港股2025-02-20

热点栏目自选股数据中心行情中心资金流向模拟交易客户端　　腾盛博药-B（02137）逆市上涨21.77%，现报1.51港元，成交额2764.64万港元。　　高盛认为，中国政府近年来推出的一系列创新激励政策，正在为生物科技企业创造更加有利的发展环境。2024年《全链条支持创新药发展实施方案》的出台，进一步优化了药品审评审批、医保支付、投融资等政策环境，为创新药企业提供了强有力的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2512461260?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-20 11:40","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2512461260","market":"hk","top_or_hot":-1,"title":"腾盛博药-B逆市涨逾22% 高盛预计头部企业将不断提高运营效率","media":"新浪港股","content":"<div>\n<p>热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　腾盛博药-B（02137）逆市上涨21.77%，现报1.51港元，成交额2764.64万港元。\n　　高盛认为，中国政府近年来推出的一系列创新激励政策，正在为生物科技企业创造更加有利的发展环境。2024年《全链条支持创新药发展实施方案》的出台，进一步优化了药品审评审批、医保支付、投融资等政策环境，为创新药企业提供了强有力的...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-20/doc-inemcarf3880265.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>腾盛博药-B逆市涨逾22% 高盛预计头部企业将不断提高运营效率</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n腾盛博药-B逆市涨逾22% 高盛预计头部企业将不断提高运营效率\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-20 11:40 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-20/doc-inemcarf3880265.shtml><strong>新浪港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　腾盛博药-B（02137）逆市上涨21.77%，现报1.51港元，成交额2764.64万港元。\n　　高盛认为，中国政府近年来推出的一系列创新激励政策，正在为生物科技企业创造更加有利的发展环境。2024年《全链条支持创新药发展实施方案》的出台，进一步优化了药品审评审批、医保支付、投融资等政策环境，为创新药企业提供了强有力的...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-20/doc-inemcarf3880265.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1791807156.HKD","symbol_name":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-20/doc-inemcarf3880265.shtml","article_id":"2512461260","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512461260","pubTimestamp":1740022800,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　腾盛博药-B逆市上涨21.77%，现报1.51港元，成交额2764.64万港元。　　高盛认为，中国政府近年来推出的一系列创新激励政策，正在为生物科技企业创造更加有利的发展环境。高盛指出，中国作为创新来源地的地位日益凸显，并将在全球范围内获得更广泛的认可。该行持续看好中国的领先生物科技公司，预计数家头部企业将在强劲的销售增长和严格的支出控制下不断提高运营效率，从而在2025/26年实现收支平衡。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","02137":"腾盛博药-B","BK4504":"桥水持仓","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","BK4588":"碎股","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","BK4550":"红杉资本持仓","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","BK4552":"Archegos爆仓风波概念","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE0004086264.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"A\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","BK1161":"生物科技","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0106831901.USD":"贝莱德世界金融基金A2","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK1587":"次新股","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK1574":"生物医药B类股","BK4127":"投资银行业与经纪业","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","BK4516":"特朗普概念","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD"},"translate_title":"Tengsheng Boyao-B bucked the market trend and rose more than 22%. Goldman Sachs expects leading companies to continue to improve operational efficiency","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":1},"content_text":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　腾盛博药-B（02137）逆市上涨21.77%，现报1.51港元，成交额2764.64万港元。\n　　高盛认为，中国政府近年来推出的一系列创新激励政策，正在为生物科技企业创造更加有利的发展环境。2024年《全链条支持创新药发展实施方案》的出台，进一步优化了药品审评审批、医保支付、投融资等政策环境，为创新药企业提供了强有力的政策保障。高盛指出，中国作为创新来源地的地位日益凸显，并将在全球范围内获得更广泛的认可。该行持续看好中国的领先生物科技公司，预计数家头部企业将在强劲的销售增长和严格的支出控制下不断提高运营效率，从而在2025/26年实现收支平衡。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2512461260","isCrawlerRequest":true}